Glycemic Response to Two Enteral Formulas in Persons With Type 2 Diabetes Mellitus

Nestlé

Status

Completed

Conditions

Diabetes

Treatments

Other: Enteral Nutrition Formula

Study type

Interventional

Funder types

Industry

Identifiers

16.17.CLI

Details and patient eligibility

About

This will be a randomized, cross-over design. Subjects will be randomized to one of two interventions on two separate study days, 1 week apart.

Enrollment

12 patients

Sex

All

Ages

20 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 20-75 yrs
Type 2 diabetes controlled with diet or diet and oral agent, with the exception of sulfonylureas such as glimepiride (Amaryl), glipizide, Glucotrol/GlucotrolXL) and glyburide (DiaBeta, Micronase, (Glynase Prestabs); meglitinides such as reaglinide (Prandin) and nateglinide (Starlix); and alphaglucosidase inhibitors such as acarbose (Precose) and miglitol (Glyset)
Hemoglobin A1C less than 9.0%
Fasting blood glucose less than 180 mg

Exclusion criteria

Abnormal thyroid function
Creatinine >2.0 mg/dL
Potassium <3.5 mEq/L
Gastrointestinal disease: ulcer, gastritis, diarrhea, gastroparesis, vomiting
History of bypass surgery, midface trauma, esophageal varices, coagulation abnormalities
Patients currently on any anti-coagulant medication
Currently unstable diabetes or under treatment for cancer, heart disease, renal disease
Unable to give informed consent or follow instructions
Current insulin therapy or insulin therapy within the past month
Patient who are pregnant
Allergies to milk, fish oil or any component of the test product
Patient who in the Investigators assessment cannot be expected to comply with treatment
Currently participating or having participated in another clinical trial.